Cecal Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Cecal Benign Neoplasm

MalaCards integrated aliases for Cecal Benign Neoplasm:

Name: Cecal Benign Neoplasm 12 17
Cecal Neoplasms 45 74
Malignant Neoplasm of Cecum 74
Neoplasm of Caecum 12
Cecum Carcinoma 74
Cecum Neoplasm 12
Cecal Neoplasm 17


External Ids:

Disease Ontology 12 DOID:1517
MeSH 45 D002430
NCIt 51 C4433
ICD10 34 C18.0

Summaries for Cecal Benign Neoplasm

Disease Ontology : 12 An intestinal benign neoplasm that is located in the cecum.

MalaCards based summary : Cecal Benign Neoplasm, also known as cecal neoplasms, is related to cecum adenoma and cecum carcinoma. The drugs Fluorouracil and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include appendix, lung and breast.

Related Diseases for Cecal Benign Neoplasm

Diseases related to Cecal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 cecum adenoma 11.4
2 cecum carcinoma 11.2

Comorbidity relations with Cecal Benign Neoplasm via Phenotypic Disease Network (PDN): (show all 13)

Active Peptic Ulcer Disease Appendix Cancer
Ascending Colon Cancer Colon Carcinoma in Situ
Colorectal Cancer Deficiency Anemia
Intestinal Obstruction Intestinal Perforation
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition Rectosigmoid Junction Neoplasm
Transverse Colon Cancer

Symptoms & Phenotypes for Cecal Benign Neoplasm

Drugs & Therapeutics for Cecal Benign Neoplasm

Drugs for Cecal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
leucovorin Approved Phase 2,Phase 1 58-05-9 143 6006
Levoleucovorin Approved, Investigational Phase 2,Phase 1 68538-85-2
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
Nintedanib Approved Phase 2 656247-17-5 56843413
nivolumab Approved Phase 2 946414-94-4
Ipilimumab Approved Phase 2 477202-00-9
Clarithromycin Approved Phase 2 81103-11-9 84029
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613
Dexlansoprazole Approved, Investigational Phase 2 138530-94-6, 103577-45-3 9578005
Lansoprazole Approved, Investigational Phase 2 103577-45-3 3883
carbamide peroxide Approved Phase 2 124-43-6
Melphalan Approved Phase 2 148-82-3 460612 4053
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
Floxuridine Approved Phase 2 50-91-9 5790
Palonosetron Approved, Investigational Phase 2 135729-61-2, 135729-56-5, 119904-90-4 148211
Calcium Approved, Nutraceutical Phase 2,Phase 1 7440-70-2 271
20 Cola Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 2,Phase 1
22 Immunosuppressive Agents Phase 2,Phase 1
23 Antidotes Phase 2,Phase 1
24 Immunologic Factors Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 2
26 Protective Agents Phase 2,Phase 1
27 Alkylating Agents Phase 2
28 Anti-Bacterial Agents Phase 2
29 Mitomycins Phase 2
30 Antimetabolites Phase 2,Phase 1
31 Calcium, Dietary Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 2
33 Anti-Infective Agents Phase 2
34 Angiogenesis Inhibitors Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 2,Phase 1
36 Antineoplastic Agents, Immunological Phase 2,Phase 1
37 Immunoglobulins Phase 1, Phase 2
38 Antibodies, Monoclonal Phase 1, Phase 2
39 Antibodies Phase 1, Phase 2
40 topoisomerase I inhibitors Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 2,Phase 1
42 Liver Extracts Phase 2,Phase 1
43 Antacids Phase 2
44 Cytochrome P-450 Enzyme Inhibitors Phase 2
45 Gastrointestinal Agents Phase 2
46 Anti-Ulcer Agents Phase 2
47 Antitubercular Agents Phase 2
48 Cytochrome P-450 CYP3A Inhibitors Phase 2
49 Proton Pump Inhibitors Phase 2
50 Antineoplastic Agents, Alkylating Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer Unknown status NCT00006112 Phase 2 chemotherapy;fluorouracil;leucovorin calcium;mitomycin C
2 Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix Completed NCT01580410 Phase 2 mitomycin C;oxaliplatin;hyperthermic intraperitoneal chemotherapy
3 Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer Completed NCT00310076 Phase 2 thalidomide
4 PIPAC for Peritoneal Metastases of Colorectal Cancer Recruiting NCT03246321 Phase 2
5 LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma Recruiting NCT03287947 Phase 2 nintedanib
6 Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors Recruiting NCT03693846 Phase 2 Nivolumab;Ipilimumab
7 Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Recruiting NCT02387203 Phase 2 PrevPac (Prevacid, Amoxicillin, Clarithromycin)
8 Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis Recruiting NCT03073694 Phase 2 Mitomycin c;Melphalan
9 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting NCT02963831 Phase 1, Phase 2 Durvalumab
10 ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis Recruiting NCT01815359 Phase 2 HIPEC with Mitomycin-C;EPIC with FUDR and Leucovorin
11 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2 Mitomycin C
12 Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia Terminated NCT00180960 Phase 2 Oxaliplatin and irinotecan
13 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
14 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
15 Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer Completed NCT00458809 Phase 1 oxaliplatin
16 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
17 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
18 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
19 Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
20 Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI Recruiting NCT02833753 Phase 1 Oxaliplatin
21 Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients Completed NCT02374411
22 Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Completed NCT01126346 Not Applicable
23 Gastrointestinal Microbiome Study of Appendiceal Cancer Recruiting NCT02599116 Not Applicable
24 Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers Recruiting NCT03604653 Mitomycin c;CDDP;CDDP;Doxorubicin
25 Selective Rather Than Routine Histopathological Examination After Appendectomy and Cholecystectomy Recruiting NCT03510923
26 International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Recruiting NCT03210298
27 Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix Not yet recruiting NCT03852693
28 EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer Terminated NCT00087191 Not Applicable EF5;motexafin lutetium

Search NIH Clinical Center for Cecal Benign Neoplasm

Cochrane evidence based reviews: cecal neoplasms

Genetic Tests for Cecal Benign Neoplasm

Anatomical Context for Cecal Benign Neoplasm

MalaCards organs/tissues related to Cecal Benign Neoplasm:

Appendix, Lung, Breast, Liver, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Cecal Benign Neoplasm:

The Cecum

Publications for Cecal Benign Neoplasm

Articles related to Cecal Benign Neoplasm:

# Title Authors Year
Malignant neoplasm of cecum in Rendu-Osler-Weber syndrome patient. ( 19817252 )

Variations for Cecal Benign Neoplasm

Expression for Cecal Benign Neoplasm

Search GEO for disease gene expression data for Cecal Benign Neoplasm.

Pathways for Cecal Benign Neoplasm

GO Terms for Cecal Benign Neoplasm

Sources for Cecal Benign Neoplasm

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....